Last reviewed · How we verify
NCT05580991
Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors
Phase 1 trial testing CAN1012 in Solid Tumor in 27 participants. Participants enrolled and being followed up; not accepting new ones.
30 June 2025
Quick facts
| Lead sponsor | Canwell Biotech Limited |
|---|---|
| Phase | Phase 1 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 27 |
| Start date | 9 September 2022 |
| Primary completion | 30 June 2025 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- CAN1012 — full drug profile →
Conditions studied
- Solid Tumor — all drugs for Solid Tumor →
Sponsor
Canwell Biotech Limited — full company profile →
Who can join
18 and older, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate CAN1012 when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Harnessing innate immune pathways for therapeutic advancement in cancer.
Hu A, Sun L, Lin H, Liao Y, et al · · 2024 · cited 150× · PMID 38523155 · DOI 10.1038/s41392-024-01765-9 -
Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies.
Mantooth SM, Abdou Y, Saez-Ibañez AR, Upadhaya S, et al · · 2024 · cited 13× · PMID 38803496 · DOI 10.3389/fimmu.2024.1385484
Verify or expand the search:
- PubMed search for NCT05580991
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CAN1012
Trials testing the same drug.
- NCT06410703 — CAN1012 Combined With PD-1 in Patients With Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT04987112 — Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors · Phase 1 · unknown
Other recruiting trials for Solid Tumor
Currently open trials in the same condition.
- NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
- NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
- NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting
Other Canwell Biotech Limited trials
Trials by the same sponsor.
- NCT06410703 — CAN1012 Combined With PD-1 in Patients With Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT06332430 — Intratumoral CAN2109 in Subjects With Solid Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05580991 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Canwell Biotech Limited
- Last refreshed: 13 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05580991.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing